share_log

Delivra Health and Its Brands LivRelief(TM) and Dream Water(R) Report Results for Second Quarter of Fiscal 2024

Delivra Health and Its Brands LivRelief(TM) and Dream Water(R) Report Results for Second Quarter of Fiscal 2024

Delivra Health 及其品牌 LivRelief (TM) 和 Dream Water (R) 公佈了2024財年第二季度業績
newsfile ·  02/27 20:30

Vancouver, British Columbia--(Newsfile Corp. - February 27, 2024) - Delivra Health Brands Inc. (TSXV: DHB) (OTCQB: DHBUF) ("Delivra Health" or the "Company"), a consumer packaged goods company uniquely positioned in the health and wellness sector, is pleased to announce its financial and operating results for the three and six months ended December 31, 2023. The Delivra Health portfolio features innovative brands Dream Water and LivRelief, which deliver relief from common health issues such as sleeplessness, chronic pain and anxiety.

不列顛哥倫比亞省溫哥華--(Newsfile Corp.,2024 年 2 月 27 日)— Delivra Health Brands Inc.(多倫多證券交易所股票代碼:DHB)(場外交易代碼:DHBUF)(”德利維拉健康“或者”公司“)是一家在健康和保健領域處於獨特地位的包裝消費品公司,很高興地宣佈其截至2023年12月31日的三個月和六個月的財務和經營業績。Delivra Health產品組合以創新品牌Dream Water和LivRelief爲特色,可緩解失眠、慢性疼痛和焦慮等常見健康問題。

Management Commentary

管理層評論

"The results of the second quarter of fiscal 2024 ("Q2 2024") demonstrates that the Company's business model is a resilient model, that works well with changes in sales volume when it comes to producing sustainable margins. The Company is on track, producing an over 39% increase in year-over-year net revenue and positive year to date EBITDA," said Gord Davey, President and Chief Executive Officer of Delivra Health. During Q2 2024, the Company focused on increasing its marketing activity and investing in consumer promotional programs in the U.S., in addition to new product listings, new customer listings and other new initiatives that will deliver an impact in future quarters. The Company will continue to expand its product portfolio in North America and abroad in multiple markets and channels."

“2024財年第二季度的業績(”2024 年第二季度“)表明該公司的商業模式是一種彈性模式,在創造可持續利潤率方面,可以很好地適應銷售量的變化。該公司已步入正軌,淨收入同比增長39%以上,年初至今的息稅折舊攤銷前利潤爲正。” Delivra Health總裁兼首席執行官戈德·戴維說。在2024年第二季度,除了新產品清單、新客戶清單和其他將在未來幾個季度產生影響的新舉措外,該公司還專注於增加其營銷活動和投資美國的消費者促銷計劃。該公司將繼續在北美和國外的多個市場和渠道中擴大其產品組合。”

Financial Highlights for the Three Months Ended December 31, 2023
(Expressed in thousands of Canadian dollars, except share and per share amounts)

截至2023年12月31日的三個月的財務摘要
(以千加元表示,股票和每股金額除外)

Net revenue: In the three months ended December 31, 2023, the Company reported total net revenue from continued operations of $2,050 as compared to $2,392 in same period last year, representing an approximate 14% reduction. This net reduction was primarily due to lower sales of Dream Water in the U.S. as a result of timing of customer ordering patterns and higher sales of the Company's licensed LivRelief cannabis-infused topical creams in Canada.

淨收入: 在截至2023年12月31日的三個月中,該公司報告持續經營的總淨收入爲2,050美元,而去年同期爲2392美元,下降了約14%。淨減少的主要原因是Dream Water在美國的銷量下降,這是由於客戶訂購模式的時機以及該公司獲得許可的LivRelief注入大麻的外用藥膏在加拿大的銷量增加。

Gross profit and gross profit margin: In the three months ended December 31, 2023, the Company reported gross profit of $1,104 and a gross profit margin of 54% as compared to $987 and 41% in the same period last year. The increase in gross profit and gross profit margin was the result of a greater proportion of high-profit customers as compared to the customer mix in the prior year.

毛利和毛利率: 在截至2023年12月31日的三個月中,該公司公佈的毛利爲1,104美元,毛利率爲54%,而去年同期爲987美元,爲41%。毛利和毛利率的增長是由於與上一年的客戶組合相比,高利潤客戶的比例有所增加。

Expenses including selling, general and administrative ("SG&A") expenses and excluding non-cash items: In the three months ended December 31, 2023, the Company reported expenses of $1,263 as compared to $968 in the same period last year, representing a $295 or 30% increase. The increase was mainly driven by the implementation of new marketing campaigns and digital marketing programs.

費用包括銷售、一般和管理(“SG&A”)費用,不包括非現金項目:在截至2023年12月31日的三個月中,該公司報告的支出爲1,263美元,而去年同期爲968美元,增長了295美元,增長了30%。增長主要是由新的營銷活動和數字營銷計劃的實施所推動的。

Adjusted EBITDA(1): In the three months ended December 31, 2023, the Company reported Adjusted EBITDA of $(84) as compared to $140 in the same period last year, representing a $224 year-over-year reduction. This reduction in Adjusted EBITDA is the result of lower net revenue compared to the prior year and higher SG&A expenses as explained above.

調整後 EBITDA(1): 在截至2023年12月31日的三個月中,該公司報告調整後的息稅折舊攤銷前利潤爲84美元,而去年同期爲140美元,同比減少224美元。如上所述,調整後息稅折舊攤銷前利潤的減少是淨收入與去年相比減少以及銷售和收購費用增加的結果。

Financial Highlights for the Six Months Ended December 31, 2023
(Expressed in thousands of Canadian dollars, except share and per share amounts)

截至2023年12月31日的六個月的財務摘要
(以千加元表示,股票和每股金額除外)

Net revenue: In the six months ended December 31, 2023, the Company reported total net revenue from continued operations of $5,722 compared to $4,121 in same period last year which is approximately a 39% increase. This increase was due to higher sales of Dream Water in U.S.

淨收入: 在截至2023年12月31日的六個月中,該公司報告的持續經營淨收入總額爲5,722美元,而去年同期爲4,121美元,增長了約39%。這一增長是由於夢之水在美國的銷量增加。

Gross profit and gross profit margin: In the six months ended December 31, 2023, the Company reported year-to-date gross profit of $3,027 and a gross profit margin of 53% as compared to $1,865 and 45% in same period last year. The increase in gross profit and gross profit margin was the result of increased sales volume and improved customer mix, which was supported by disciplined operational costs.

毛利和毛利率: 在截至2023年12月31日的六個月中,該公司公佈的年初至今毛利爲3,027美元,毛利率爲53%,而去年同期爲1,865美元,爲45%。毛利和毛利率的增長是銷售量增加和客戶組合改善的結果,這得到了嚴格的運營成本的支持。

Expenses including SG&A expenses and excluding non-cash items: In the six months ended December 31, 2023, the Company reported expenses of $2,579 compared to $2,012 in the same period last year, representing a 28% increase. As noted previously, the increase was mainly driven by the implementation of new marketing campaigns and digital marketing programs.

費用包括銷售和收購費用,不包括非現金項目:在截至2023年12月31日的六個月中,該公司報告的支出爲2579美元,而去年同期爲2,012美元,增長了28%。如前所述,增長主要是由新的營銷活動和數字營銷計劃的實施推動的。

Adjusted EBITDA(1): In the six months ended December 31, 2023, the Company reported Adjusted EBITDA of $601 compared to $(15) in the same period last year, representing a $616 year-over-year improvement. This increase in Adjusted EBITDA was driven by management's focus on the right customer mix and margin improvement, which was supported by effective administrative and selling support functions.

調整後 EBITDA(1): 在截至2023年12月31日的六個月中,該公司報告調整後的息稅折舊攤銷前利潤爲601美元,而去年同期爲15美元,同比增長616美元。調整後息稅折舊攤銷前利潤的增長是由管理層對正確的客戶組合和利潤率提高的關注所推動的,這得到了有效的管理和銷售支持職能的支持。

Summary of Key Financial Results

主要財務業績摘要

For the three months ended
December 31
For the six months ended
December 31
($000's, except share and per share amounts) 2023 2022 2023 2022
Continued operations: $ $ $ $
Net revenue 2,050 2,392 5,722 4,121
Cost of sales 871 1,284 2,542 2,124
Inventory write-down 75 121 153 132
Gross profit 1,104 987 3,027 1,865
Expenses excluding non-cash expenses 1,263 968 2,579 2,012
Depreciation and amortization and share based compensation 327 410 662 781
Total expenses 1,590 1,378 3,241 2,793
Loss from operations (486) (391) (214) (928)
Other (expense) income (163) 1,281 (207) 1,434
Net gain (loss) from continued operations (649) 890 (421) 506
Net gain (loss) per share - basic (0.002) 0.004 (0.002) 0.002
Net gain (loss) per share -diluted (0.002) 0.003 (0.001) 0.002
在結束的三個月裏
12 月 31 日
在截至的六個月中
12 月 31 日
(000美元,股票和每股金額除外) 2023 2022 2023 2022
持續運營: $ $ $ $
淨收入 2,050 2,392 5,722 4,121
銷售成本 871 1,284 2,542 2,124
庫存減記 75 121 153 132
毛利 1,104 987 3,027 1,865
不包括非現金支出的費用 1,263 968 2,579 2,012
折舊和攤銷以及基於股份的薪酬 327 410 662 781
支出總額 1,590 1,378 3,241 2,793
運營損失 (486) (391) (214) (928)
其他(支出)收入 (163) 1,281 (207) 1,434
持續經營的淨收益(虧損) (649) 890 (421) 506
每股淨收益(虧損)——基本 (0.002) 0.004 (0.002) 0.002
每股淨收益(虧損)——攤薄 (0.002) 0.003 (0.001) 0.002

Adjusted EBITDA(1) (non-IFRS measure)

調整後 EBITDA(1) (非國際財務報告準則衡量標準)

For the three months ended
December 31
For the six months ended
December 31
($000's, except share and per share amounts) 2023 2022 2023 2022
Loss from operations (486) (391) (214) (928)
Inventory write-down 75 121 153 132
Depreciation and amortization 326 332 659 664
Share-based compensation 1 78 3 117
Adjusted EBITDA(1) (84) 140 601 (15)
在結束的三個月裏
12 月 31 日
在截至的六個月中
12 月 31 日
(000美元,股票和每股金額除外) 2023 2022 2023 2022
運營損失 (486) (391) (214) (928)
庫存減記 75 121 153 132
折舊和攤銷 326 332 659 664
基於股份的薪酬 1 78 3 117
調整後的息稅折舊攤銷前利潤 (1) (84) 140 601 (15)

Expenses excluding non-cash items

不包括非現金項目的費用

For the three months ended
December 31
For the six months ended
December 31
($000's, except share and per share amounts) 2023 2022 2023 2022
General and administration 933 888 1,846 1,853
Sales and marketing 330 80 733 159
Total 1,263 968 2,579 2,012
在結束的三個月裏
12 月 31 日
在截至的六個月中
12 月 31 日
(000美元,股票和每股金額除外) 2023 2022 2023 2022
一般和行政 933 888 1,846 1,853
銷售和營銷 330 80 733 159
總計 1,263 968 2,579 2,012

About Delivra Health Brands Inc.

關於 Delivra 健康品牌公司

Helping people take control of their health with alternative wellness solutions is what energizes the Delivra Health team! The Delivra Health portfolio features innovative brands like Dream Water and LivRelief, which deliver relief from common everyday issues like chronic pain, anxiety, and sleeplessness. Delivra Health products have allowed millions of customers to reclaim their mobility, energy, and in turn, quality of life. The websites of the Company's two subsidiaries are Dream Water and LivReliefTM. For more information, please visit .

通過替代健康解決方案幫助人們控制自己的健康是Delivra Health團隊的動力!Delivra Health產品組合以Dream Water和LivRelief等創新品牌爲特色,這些品牌可以緩解慢性疼痛、焦慮和失眠等常見的日常問題。Delivra Health 產品使數百萬客戶能夠回收他們的出行能力、能源,進而提高生活質量。該公司兩家子公司的網站是 Dream Water 和 LivReliefTM。欲了解更多信息,請訪問。

Non-IFRS Measures, Reconciliation and Discussion

非國際財務報告準則衡量標準、對賬和討論

This press release contains references to "Adjusted EBITDA" which is a non-International Financial Reporting Standards ("IFRS") financial measure. Adjusted EBITDA is a measure of the Company's profit from operations before interest, taxes, depreciation, and amortization and adjusted for share-based compensation, common shares issued for services, fair value effects of accounting for biological assets and inventories, asset impairment and write-downs, and other non-cash items, and is a non-IFRS measure.

本新聞稿提及 “調整後的息稅折舊攤銷前利潤”,這是一項非國際財務報告準則(”國際財務報告準則“)財務衡量標準。調整後的息稅折舊攤銷前利潤是衡量公司扣除利息、稅項、折舊和攤銷前的運營利潤的指標,並根據基於股份的薪酬、爲服務而發行的普通股、生物資產和存貨會計的公允價值影響、資產減值和減記以及其他非現金項目進行了調整,是一項非國際財務報告準則衡量標準。

This measure can be used to analyze and compare profitability among companies and industries, as it eliminates the effects of financing and capital expenditures. It is often used in valuation ratios and can be compared to enterprise value and revenue. This measure does not have any standardized meaning according to IFRS and, therefore, may not be comparable to similar measures presented by other companies.

該衡量標準可以用來分析和比較公司和行業之間的盈利能力,因爲它消除了融資和資本支出的影響。它通常用於估值比率,可以與企業價值和收入進行比較。根據國際財務報告準則,該衡量標準沒有任何標準化含義,因此可能無法與其他公司提出的類似衡量標準相提並論。

There are no comparable IFRS financial measures presented in Delivra Health's financial statements. Reconciliations of the supplemental non-IFRS measure are presented in the Company's management discussion and analysis for the three and six months ended December 31, 2023. This non-IFRS financial measure is presented because management has evaluated the financial results both including and excluding the adjusted items and believes that the non-IFRS financial measure presented provides additional perspective and insights when analyzing the core operating performance of the business. The Company believes that the supplemental measure provides information which is useful to shareholders and investors in understanding the Company's performance and may assist in the evaluation of the Company's business relative to that of its peers.

Delivra Health的財務報表中沒有列出可比的國際財務報告準則財務指標。補充非國際財務報告準則指標的對賬情況載於公司截至2023年12月31日的三個月和六個月的管理層討論和分析中。之所以提出這項非國際財務報告準則財務指標,是因爲管理層評估了包括和不包括調整後項目的財務業績,並認爲所提出的非國際財務報告準則財務指標在分析業務的核心經營業績時提供了更多的視角和見解。公司認爲,補充衡量標準提供的信息有助於股東和投資者了解公司的業績,並可能有助於評估公司相對於同行的業務。

The non-IFRS financial measure should not be considered superior to, as a substitute for, or as an alternative to, and should be considered in conjunction with the IFRS financial measures presented in the Company's financial statements. For more information, please see "Adjusted EBITDA (non-IFRS measure)" and "Non-IFRS Measures" in the Company's management discussion and analysis for the three and six months ended December 31, 2023, which is available under the Company's SEDAR+ profile on .

不應將非國際財務報告準則財務指標視爲優於、替代或替代品,應將其與公司財務報表中列報的國際財務報告準則財務指標結合起來考慮。欲了解更多信息,請參閱公司管理層對截至2023年12月31日的三個月和六個月的討論和分析中的 “調整後的息稅折舊攤銷前利潤(非國際財務報告準則指標)” 和 “非國際財務報告準則指標”,該討論和分析可在公司的SEDAR+簡介中查閱。

Notes:

注意事項:

  1. This is a non-IFRS reporting measure. For a reconciliation of this measure to the nearest IFRS measure, see "Adjusted EBITDA (non-IFRS measure)" and "Non-IFRS Measures" in the Company's management discussion and analysis for the three and six months ended December 31, 2023.
  1. 這是一項非國際財務報告準則的報告指標。有關該指標與最接近的國際財務報告準則指標的對賬,請參閱公司管理層討論和分析中截至2023年12月31日的三個月和六個月中的 “調整後的息稅折舊攤銷前利潤(非國際財務報告準則指標)” 和 “非國際財務報告準則指標”。

Cautionary Note Regarding Forward-Looking Statements

關於前瞻性陳述的警示說明

This news release contains "forward-looking information" and "forward-looking statements" (collectively, "forward-looking statements") within the meaning of the applicable Canadian securities legislation. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates, and projections as at the date of this news release. Any statement that involves discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as "expects", or "does not expect", "is expected", "anticipates" or "does not anticipate", "plans", "budget", "scheduled", "forecasts", "estimates", "believes" or "intends" or variations of such words and phrases or stating that certain actions, events or results "may" or "could", "would", "might" or "will" be taken to occur or be achieved) are not statements of historical fact and may be forward-looking statements. In this news release, forward-looking statements include, among other things, statements with respect to the Company's products offering relief from chronic pain, anxiety, and sleeplessness; statements about the Company's business model and the ability to produce sustainable margins; statements regarding the impact of new marketing activity, promotional programs, new product listings, new customer listings, and other new initiatives; statements relating to the expansion of the Company's product portfolio; expectations regarding increase of the Company's revenues and profitability; and statements regarding the Company's growth objectives.

本新聞稿包含適用的加拿大證券立法所指的 “前瞻性信息” 和 “前瞻性陳述”(統稱爲 “前瞻性陳述”)。除歷史事實陳述外,所有陳述均爲前瞻性陳述,基於截至本新聞發佈之日的預期、估計和預測。任何涉及對預測、期望、信念、計劃、預測、目標、假設、未來事件或績效的討論的陳述(通常但並非總是使用 “期望”、“不期望”、“預期” 或 “不預期”、“計劃”、“預算”、“預算”、“預期”、“預測”、“估計”、“相信” 或 “打算” 等詞語或此類詞語的變體)以及短語或陳述 “可能” 或 “可能”、“將”、“可能” 或 “將” 發生或實現的某些行動、事件或結果)不是陳述歷史事實,可能是前瞻性陳述。在本新聞稿中,前瞻性陳述除其他外包括有關公司緩解慢性疼痛、焦慮和失眠的產品的陳述;有關公司商業模式和創造可持續利潤能力的陳述;有關新營銷活動、促銷計劃、新產品清單、新客戶清單和其他新舉措影響的陳述;與擴大公司產品組合有關的聲明;對公司收入增長的預期和盈利能力;以及有關公司增長目標的聲明。

These forward-looking statements are based on reasonable assumptions and estimates of management of the Company at the time such statements were made. Actual future results may differ materially as forward-looking statements involve known and unknown risks, uncertainties, and other factors which may cause the actual results, performance, or achievements of the Company to materially differ from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors, among other things, include: fluctuations in general macroeconomic conditions; fluctuations in securities markets; expectations regarding the size of the cannabis markets where the Company operates; changing consumer habits; the ability of the Company to successfully achieve its business objectives; plans for expansion; political and social uncertainties; inability to obtain adequate insurance to cover risks and hazards; employee relations and the presence of laws and regulations that may impose restrictions on cultivation, production, distribution, and sale of cannabis and cannabis-related products in the markets where the Company operates. Although the forward-looking statements contained in this news release are based upon what management of the Company believes, or believed at the time, to be reasonable assumptions, the Company cannot assure shareholders that actual results will be consistent with such forward-looking statements, as there may be other factors that cause results not to be as anticipated, estimated or intended. Readers should not place undue reliance on the forward-looking statements and information contained in this news release. The Company assumes no obligation to update the forward-looking statements of beliefs, opinions, projections, or other factors, should they change, except as required by law.

這些前瞻性陳述基於發表此類陳述時公司管理層的合理假設和估計。未來的實際業績可能存在重大差異,因爲前瞻性陳述涉及已知和未知的風險、不確定性和其他因素,這些因素可能導致公司的實際業績、業績或成就與此類前瞻性陳述所表達或暗示的任何未來業績、業績或成就存在重大差異。這些因素包括:總體宏觀經濟狀況的波動;證券市場的波動;對公司經營的大麻市場規模的預期;消費者習慣的改變;公司成功實現業務目標的能力;擴張計劃;政治和社會不確定性;無法獲得足夠的保險來承保風險和危險;員工關係以及可能限制種植、生產、分銷的法律和法規的存在,以及在公司經營的市場上銷售大麻和大麻相關產品。儘管本新聞稿中包含的前瞻性陳述基於公司管理層當時認爲或認爲的合理假設,但公司無法向股東保證實際業績將與此類前瞻性陳述一致,因爲可能還有其他因素導致業績與預期、估計或預期不符。讀者不應過分依賴本新聞稿中包含的前瞻性陳述和信息。除非法律要求,否則公司沒有義務在信念、觀點、預測或其他因素的前瞻性陳述發生變化時對其進行更新。

Additional information regarding this and other risks and uncertainties relating to the Company's business are contained under the heading "Risk Factors" in the Company's annual information form dated March 2, 2021, and under the heading "Risks and Uncertainties" in the Company's management's discussion and analysis dated February 27, 2024 for the three and six months ended December 31, 2023 filed under the Company's profile on SEDAR+ at .

有關該風險以及與公司業務相關的其他風險和不確定性的其他信息包含在公司2021年3月2日的年度信息表中 “風險因素” 標題下,以及公司管理層於2024年2月27日根據公司在SEDAR+的簡介提交的截至2023年12月31日的三個月和六個月的討論和分析中的 “風險和不確定性” 標題下。

Neither the TSX-V nor its Regulation Services Provider (as that term is defined in the policies of the TSX-V) accept responsibility for the adequacy or accuracy of this release.

多倫多證券交易所及其監管服務提供商(該術語在多倫多證券交易所的政策中定義)均不對本新聞稿的充分性或準確性承擔責任。

Investor Relations:
Jack Tasse
Chief Financial Officer
IR@delivrahealth.com
1-877-915-7934

投資者關係:
傑克·塔斯
首席財務官
IR@delivrahealth.com
1-877-915-7934

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論